(S)-12-((R)-7,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,
2986084-03-9
Pharmaceutical Grade
90%
Shanghai Port or Shenzhen Port
H&D
A temperature-controlled box with a capacity of up to 10g
2025-05-31
Drug impurity reference,Impurity reference,Reference substance,impurity
-
Product Details
-
Seller Information
-
DescriptionBasic Info
-
Product Name:
Baloxavir Enantiomer
Other Name:Baloxavir Enantiomer;1H-[1,4]Oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione, 12-[(11R)-7,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl]-3,4,12,12a-tetrahydro-7-hydroxy-, (12aS)-rel-
CAS No.:2986084-03-9
Molecular Formula:C24H19F2N3O4S
Molecular Weight:483.49
Categories:
Characteristics-
Density:
1.632±0.10 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted)
Boiling Point:644.675±65.00 °C(Press: 760.00 Torr)(predicted)
PKA:4.500±1.00(predicted)
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Drug impurity reference,Impurity reference,Reference substance,impurity
-
Location:
Hengfeng Wanda (Hubei) Pharmaceutical Technology Co., LTD., Hongshan District, Wuhan City, Hubei Province, China
-
Payment Terms:
TT against copy of documents,100% TT in advance
-
Average lead Time:
150 days
-
Total Annual Revenue:
$5 million-$10 million
-
Total Employees:
51-100
-
Year of Establishment:
2023
Company Certificates-
Brand certification certificate
-
QUALITY MANAGEMENT SYSTEM CERTIFICATE
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product
More from this Seller
-
-
-
Upadacitinib Impurity 21-- (3R,4S)-benzyl 3-(2-chloroacetyl)-4-ethylpyrrolidine-1-carboxylate
Pharmaceutical Grade / 90%
-
-
-
-
Dapagliflozin Impurity 11-- (2S,3R,4R,5R)-1-(4-chloro-3-(4-ethoxybenzyl)phenyl)hexane-1,2,3,4,5,6-hexaol
Pharmaceutical Grade / 90%
-
-
-
-
Upadacitinib Impurity 1((3S,4S)-benzyl 3-(2-bromoacetyl)-4-ethylpyrrolidine-1-carboxylate)
Pharmaceutical Grade / 90%
-